<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01545518</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00052646</org_study_id>
    <secondary_id>BT11-000312</secondary_id>
    <nct_id>NCT01545518</nct_id>
  </id_info>
  <brief_title>IVIG Treatment for Refractory Immune-Related Adult Epilepsy</brief_title>
  <official_title>IVIG Treatment for Refractory Immune-Related Adult Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the initial screening study is to find out if immune problems are an
      unrecognized cause of epilepsy in some patients. This study consists of a single blood
      sample, which will be tested for possible immune abnormalities. If enough patients are found
      who show immune abnormalities, those patients who are still having uncontrolled seizures will
      be invited to participate in a study of immune treatment with a compound called intravenous
      immunoglobulin (IVIG).

      The study hypothesis is that a significant proportion of the young-onset, refractory,
      image-negative, partial-onset epilepsy population have an underlying autoimmune disorder, and
      many of these patients will respond to immune therapies, including IVIG.

      At present, the importance of immune abnormalities in causing epilepsy, and the proper
      treatment when they are found, are both poorly understood. The investigators hope that this
      study will help us understand the cause of some cases that are difficult to treat.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is divided into two phases:

      Phase I: The investigators will screen for evidence of neuronal nuclear, cytoplasmic, and
      cell surface autoantibodies in our population of new onset refractory, imaging-negative young
      adult epilepsy patients. This part of the study involves obtaining a single blood sample,
      equal to about 2 teaspoons.

      Phase 2: If a sufficient number of cases are identified, a double-blind crossover study of
      IVIG treatment will be performed in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility criteria, unable for Phase 2 of study, &amp; phase 1 was terminated.
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune Abnormalities</measure>
    <time_frame>Screening visit</time_frame>
    <description>neuronal nuclear, cytoplasmic, and cell surface autoantibodies</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Epilepsy, Cryptogenic</condition>
  <condition>Epilepsy, Partial</condition>
  <condition>Seizure Disorder</condition>
  <condition>Autoimmune Diseases, Nervous System</condition>
  <condition>Limbic Encephalitis</condition>
  <arm_group>
    <arm_group_label>all subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IVIG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVIG</intervention_name>
    <description>IVIG 2 mg/kg in two divided doses with placebo crossover</description>
    <arm_group_label>all subjects</arm_group_label>
    <other_name>IVIG manufactured by Baxter Healthcare Corporation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of uncontrolled epilepsy with at least two seizures a month for three
             consecutive months.

          -  Age 18 to 50.

          -  Clinical semiology or electroencephalogram (EEG) consistent with partial onset
             epilepsy.

          -  Refractory to an adequate trial of two or more main-line anti-epileptic drugs.

          -  Ability to keep a seizure diary.

          -  Normal brain magnetic resonance imaging (MRI) - 3 Tesla, seizure protocol; with the
             exception of hippocampal sclerosis

        Exclusion Criteria:

          -  History of severe prematurity or neonatal distress, febrile seizures, moderate or
             sever traumatic brain injury, stroke, brain tumor, meningitis, encephalitis,
             neurocutaneous syndromes, or intracranial metal objects.

          -  Evidence of psychogenic epilepsy.

          -  History of convulsive status epilepticus.

          -  History of primary generalized epilepsy in a first degree relative.

          -  Known serious medical illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles M. Epstein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Alamowitch S, Graus F, Uchuya M, Reñé R, Bescansa E, Delattre JY. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain. 1997 Jun;120 ( Pt 6):923-8.</citation>
    <PMID>9217677</PMID>
  </reference>
  <reference>
    <citation>Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001 Jun;124(Pt 6):1138-48.</citation>
    <PMID>11353730</PMID>
  </reference>
  <reference>
    <citation>Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000 Jul;123 ( Pt 7):1481-94.</citation>
    <PMID>10869059</PMID>
  </reference>
  <reference>
    <citation>Jacobs DA, Fung KM, Cook NM, Schalepfer WW, Goldberg HI, Stecker MM. Complex partial status epilepticus associated with anti-Hu paraneoplastic syndrome. J Neurol Sci. 2003 Sep 15;213(1-2):77-82.</citation>
    <PMID>12873758</PMID>
  </reference>
  <reference>
    <citation>Lawn ND, Westmoreland BF, Kiely MJ, Lennon VA, Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc. 2003 Nov;78(11):1363-8.</citation>
    <PMID>14601695</PMID>
  </reference>
  <reference>
    <citation>Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998 Mar;50(3):652-7.</citation>
    <PMID>9521251</PMID>
  </reference>
  <reference>
    <citation>McKeon A, Ahlskog JE, Britton JW, Lennon VA, Pittock SJ. Reversible extralimbic paraneoplastic encephalopathies with large abnormalities on magnetic resonance images. Arch Neurol. 2009 Feb;66(2):268-71. doi: 10.1001/archneurol.2008.556. Erratum in: Arch Neurol. 2011 Mar;68(3):371. Britton, Jeffrey A [corrected to Britton, Jeffrey W].</citation>
    <PMID>19204167</PMID>
  </reference>
  <reference>
    <citation>Nahab F, Heller A, Laroche SM. Focal cortical resection for complex partial status epilepticus due to a paraneoplastic encephalitis. Neurologist. 2008 Jan;14(1):56-9. doi: 10.1097/NRL.0b013e3181578952.</citation>
    <PMID>18195661</PMID>
  </reference>
  <reference>
    <citation>Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004 Nov;56(5):715-9.</citation>
    <PMID>15468074</PMID>
  </reference>
  <reference>
    <citation>Porta-Etessam J, Ruiz-Morales J, Millan JM, Ramos A, Martínez-Salio A, Berbel-García A. Epilepsia partialis continua and frontal features as a debut of anti-Hu paraneoplastic encephalomyelitis with focal frontal encephalitis. Eur J Neurol. 2001 Jul;8(4):359-60.</citation>
    <PMID>11422434</PMID>
  </reference>
  <reference>
    <citation>Shavit YB, Graus F, Probst A, Rene R, Steck AJ. Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol. 1999 Feb;45(2):255-8.</citation>
    <PMID>9989630</PMID>
  </reference>
  <reference>
    <citation>Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology. 2004 Apr 13;62(7):1177-82.</citation>
    <PMID>15079019</PMID>
  </reference>
  <reference>
    <citation>Matarasso N, Bar-Shira A, Rozovski U, Rosner S, Orr-Urtreger A. Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate. Neoplasia. 2007 Sep;9(9):707-15.</citation>
    <PMID>17898866</PMID>
  </reference>
  <reference>
    <citation>Rudzinski LA, Pittock SJ, McKeon A, Lennon VA, Britton JW. Extratemporal EEG and MRI findings in ANNA-1 (anti-Hu) encephalitis. Epilepsy Res. 2011 Aug;95(3):255-62. doi: 10.1016/j.eplepsyres.2011.04.006. Epub 2011 May 12.</citation>
    <PMID>21570256</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2012</study_first_posted>
  <results_first_submitted>August 21, 2014</results_first_submitted>
  <results_first_submitted_qc>August 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 1, 2014</results_first_posted>
  <last_update_submitted>August 21, 2014</last_update_submitted>
  <last_update_submitted_qc>August 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Charles M. Epstein, MD</investigator_full_name>
    <investigator_title>Professsor of Neurology - Divsion of Epilepsy</investigator_title>
  </responsible_party>
  <keyword>Refractory epilepsy</keyword>
  <keyword>Cryptogenic epilepsy</keyword>
  <keyword>Autoimmune disorders</keyword>
  <keyword>IVIG</keyword>
  <keyword>Immunomodulatory therapy</keyword>
  <keyword>Autoantibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Limbic Encephalitis</mesh_term>
    <mesh_term>Autoimmune Diseases of the Nervous System</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients enrolled in a medical setting if eligible. Inclusion and exclusion criteria. A total of 20 patients with unexplained refractory epilepsy were screened and tested with a multiple panel for anti-neuronal antibodies.</recruitment_details>
      <pre_assignment_details>In comparisons with our original futility criteria, it was apparent that the absence of more powerful findings, and the time it took to collect the ones we have, indicated the virtual impossibility of identifying enough patients with strong autoimmune findings to carry out Phase 2 of this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>IVIG
IVIG: IVIG 2 mg/kg in two divided doses with placebo crossover</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>18-50 years of age, both male and female</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>IVIG
IVIG: IVIG 2 mg/kg in two divided doses with placebo crossover</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immune Abnormalities</title>
        <description>neuronal nuclear, cytoplasmic, and cell surface autoantibodies</description>
        <time_frame>Screening visit</time_frame>
        <population>No analysis occurred and study was terminated early due to subject numbers not eligible for the 2nd phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>IVIG
IVIG: IVIG 2 mg/kg in two divided doses with placebo crossover</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Abnormalities</title>
          <description>neuronal nuclear, cytoplasmic, and cell surface autoantibodies</description>
          <population>No analysis occurred and study was terminated early due to subject numbers not eligible for the 2nd phase of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>IVIG
IVIG: IVIG 2 mg/kg in two divided doses with placebo crossover
No AE's.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early. Subject eligibility for phase 2 not available.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Charles M. Epstein</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-3633</phone>
      <email>cepstei@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

